Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Departamento de Bioquímica, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
J Glob Antimicrob Resist. 2019 Dec;19:50-52. doi: 10.1016/j.jgar.2019.08.014. Epub 2019 Aug 24.
Here we report the draft genome sequence of Staphylococcus agnetis 3682, a strain producing agneticin 3682, a broad-spectrum lantibiotic with potential medical applications. The inhibitory activity of S. agnetis 3682 against multidrug-resistant methicillin-resistant Staphylococcus aureus (MRSA) isolates involved in human infections was also investigated.
A sequencing library was constructed using a Nextera XT DNA Library Preparation Kit. An Illumina MiSeq system was used to perform whole-genome shotgun sequencing. De novo genome assembly was performed using the A5-miseq pipeline. Staphylococcus agnetis 3628 genome annotation was performed by the RAST server, and BAGEL4 and antiSMASH v.4.0 platforms were used for mining bacteriocin gene clusters. The inhibitory activity of S. agnetis 3682 against 20 multidrug-resistant MRSA strains involved in human infections in two Brazilian hospitals was determined by the deferred antagonism assay on brain-heart infusion (BHI) agar plates.
The total scaffold size was determined to be 2 502 817bp with a G+C content of 35.6%. Genome analyses revealed 2437 coding sequences, 76 RNA genes, 27 genes involved in drug resistance and 2 bacteriocinogenic gene clusters (for agneticin 3682 and hyicin 4244). Staphylococcus agnetis 3682 inhibited 80% of the MRSA isolates tested.
This study describes the main features of the draft genome of S. agnetis 3682, a strain producing the first bacteriocin (agneticin 3682) reported in this species. A second gene cluster encoding a sactipeptide was also found in the bacterial chromosome. Agneticin 3682 shows a new potential application against clinical MRSA isolates.
本研究报告了产生广谱类菌素抗生素磁霉素 3682 的葡萄球菌菌株 3682 的基因组草案序列，该抗生素具有潜在的医学应用价值。此外，还研究了 3682 菌株对涉及人类感染的多药耐药性耐甲氧西林金黄色葡萄球菌（MRSA）分离株的抑制活性。
使用 Nextera XT DNA 文库制备试剂盒构建测序文库。使用 Illumina MiSeq 系统进行全基因组 shotgun 测序。使用 A5-miseq 管道进行从头基因组组装。通过 RAST 服务器对葡萄球菌 3628 基因组进行注释，并使用 BAGEL4 和 antiSMASH v.4.0 平台挖掘细菌素基因簇。通过在脑心浸液（BHI）琼脂平板上进行延迟拮抗试验，测定 3682 菌株对来自巴西两家医院的 20 株多药耐药性 MRSA 临床分离株的抑制活性。
总支架大小确定为 2 502 817bp，G+C 含量为 35.6%。基因组分析显示，该菌含有 2437 个编码序列、76 个 RNA 基因、27 个耐药基因和 2 个细菌素基因簇（用于产生磁霉素 3682 和海因菌素 4244）。3682 菌株抑制了 80%测试的 MRSA 分离株。
本研究描述了产生第一种该属细菌素（磁霉素 3682）的葡萄球菌菌株 3682 的基因组草案的主要特征。还在细菌染色体上发现了第二个编码 sactipeptide 的基因簇。磁霉素 3682 显示出针对临床 MRSA 分离株的新的潜在应用。
